Biosimilars in Osteoporosis: Highlights from the ASBMR

Course overview

Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency. Incorporating biosimilars into the management of osteoporosis, known as a silent chronic disease responsible for 13 million fragility fractures worldwide, provide a more affordable version of osteoporosis medication, and an alternative to conventional osteoporosis agents. During this activity, presented as a satellite symposium at the recent ASBMR Annual Meeting, experts will discuss the efficacy and safety of biosimilars, and how these agents are changing the treatment landscape in osteoporosis management.